409 related articles for article (PubMed ID: 17538164)
1. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Curran D; Giralt J; Harari PM; Ang KK; Cohen RB; Kies MS; Jassem J; Baselga J; Rowinsky EK; Amellal N; Comte S; Bonner JA
J Clin Oncol; 2007 Jun; 25(16):2191-7. PubMed ID: 17538164
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
[TBL] [Abstract][Full Text] [Related]
4. Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation.
Fang FM; Tsai WL; Chien CY; Chiu HC; Wang CJ; Chen HC; Hsiung CY
Oncology; 2005; 68(4-6):405-13. PubMed ID: 16020970
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
Bourhis J; Lefebvre JL; Vermorken JB
Eur J Cancer; 2010 Jul; 46(11):1979-89. PubMed ID: 20561781
[TBL] [Abstract][Full Text] [Related]
6. Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy.
Fang FM; Liu YT; Tang Y; Wang CJ; Ko SF
Cancer; 2004 Jan; 100(2):425-32. PubMed ID: 14716781
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Griffin S; Walker S; Sculpher M; White S; Erhorn S; Brent S; Dyker A; Ferrie L; Gilfillan C; Horsley W; Macfarlane K; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():49-54. PubMed ID: 19567214
[TBL] [Abstract][Full Text] [Related]
8. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
Bernier J; Schneider D
Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
[TBL] [Abstract][Full Text] [Related]
10. Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study.
Rathod S; Gupta T; Ghosh-Laskar S; Murthy V; Budrukkar A; Agarwal J
Oral Oncol; 2013 Jun; 49(6):634-42. PubMed ID: 23562564
[TBL] [Abstract][Full Text] [Related]
11. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
[TBL] [Abstract][Full Text] [Related]
12. Changes in quality of life of head-and-neck cancer patients following postoperative radiotherapy.
Fang FM; Chien CY; Kuo SC; Chiu HC; Wang CJ
Acta Oncol; 2004; 43(6):571-8. PubMed ID: 15370615
[TBL] [Abstract][Full Text] [Related]
13. A multidisciplinary approach to squamous cell carcinomas of the head and neck: an update.
Bernier J
Curr Opin Oncol; 2008 May; 20(3):249-55. PubMed ID: 18391622
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab in the treatment of head and neck cancer.
Bernier J
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1539-52. PubMed ID: 17134359
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in patients with oropharynx carcinomas: assessment after accelerated radiotherapy with or without chemotherapy versus radical surgery and postoperative radiotherapy.
Allal AS; Nicoucar K; Mach N; Dulguerov P
Head Neck; 2003 Oct; 25(10):833-9; discussion 839-40. PubMed ID: 12966507
[TBL] [Abstract][Full Text] [Related]
18. Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials.
Hallqvist A; Bergman B; Nyman J
Radiother Oncol; 2012 Jul; 104(1):39-44. PubMed ID: 22727262
[TBL] [Abstract][Full Text] [Related]
19. Global quality of life during the acute toxicity phase of multimodality treatment for patients with head and neck cancer: can we identify patients most at risk of profound quality of life decline?
Tribius S; Reemts E; Prosch C; Raguse M; Petersen C; Kruell A; Singer S; Bergelt C
Oral Oncol; 2012 Sep; 48(9):898-904. PubMed ID: 22502815
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
